LTS Lohmann Therapie Systeme AG to present at the J.P. Morgan 36th Annual Healthcare Conference 2018

Andernach, Germany, January 3, 2018
LTS, a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches, announced today that Dr. Tim G. Schlange, member of the LTS management board and CMO of LTS, will present at the J.P. Morgan 36th Annual Healthcare Conference 2018 to be held January 8-11th, 2018 at the Westin St. Francis Hotel in San Francisco, CA.
Details of LTS presentation are as follows:

Event: J.P. Morgan 36th Annual Healthcare Conference 2018
Date: Monday, January 8th 2018
Time: 4:00 pm (Pacific Time)
Location: Westin St. Francis Hotel, San Francisco, CA

 

About LTS Lohmann Therapie Systeme AG

LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”) and Oral Thin Films (“OTF”) for the pharmaceutical industry. LTS’s innovation model consists of both partner-funded and self-funded initiatives currently encompassing more than 20 marketed products and a deep and diverse pipeline of development projects targeting multiple disease indications. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, NJ, USA and a representation in Shanghai, China.

Media Contacts
Dr. Iris Schnitzler,
LTS Marketing und Market Services
iris.schnitzler@ltslohmann.de

LTS Lohmann Therapie-Systeme AG
Lohmannstr. 2
D- 56626 Andernach
Tel.: +49 (0) 2632 99 – 2589

2018-02-01T22:08:36+00:00Jan 3rd, 2018|Fairs|

Privacy  Imprint

This website uses cookies to analyse website accesses/marketing measures. If you continue to use this website, you agree to our use of cookies. Information about cookies and your right to object.
Ok